<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05104983</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0438</org_study_id>
    <secondary_id>1R01FD007275</secondary_id>
    <nct_id>NCT05104983</nct_id>
  </id_info>
  <brief_title>Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study</brief_title>
  <acronym>TSC-STEPS</acronym>
  <official_title>Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Darcy Krueger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Food and Drug Administration (FDA)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Medical Center, Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a Phase II randomized, double-blind, placebo controlled multi-site study to&#xD;
      evaluate the safety and efficacy of early sirolimus to prevent or delay seizure onset in TSC&#xD;
      infants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tuberous Sclerosis Complex (TSC) is caused by genetic mutation in TSC1 or TSC2, resulting in&#xD;
      dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway. Age at time of&#xD;
      seizure onset in TSC infants has been linked to long-term neurodevelopmental outcome in this&#xD;
      high-risk population. Sirolimus is an mTOR inhibitor used to treat many of the symptoms of&#xD;
      TSC, including epilepsy. This will be the first study to truly evaluate a targeted,&#xD;
      disease-modifying drug therapy for preventing or delaying seizure onset in TSC using a&#xD;
      rational, mechanism-based therapeutic approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This trial will employ a randomized, double-blind, placebo-controlled multisite design to evaluate the safety and efficacy of early sirolimus treatment to prevent or delay seizure onset in TSC infants.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy -- time to seizure onset</measure>
    <time_frame>12 months of age</time_frame>
    <description>Time to seizure onset, comparing sirolimus with placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety -- adverse events</measure>
    <time_frame>12 months of age</time_frame>
    <description>Percentage of subjects reporting severe (CTCAE v5.0 grade &gt;= 3) adverse event (AE) or serious adverse event (SAE), comparing sirolimus with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental Outcomes</measure>
    <time_frame>12 and 24 months of age</time_frame>
    <description>Neurodevelopmental outcomes at the end of treatment, comparing sirolimus with placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Outcomes</measure>
    <time_frame>12 and 24 months of age</time_frame>
    <description>Patient and caregiver quality of life, comparing sirolimus with placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EEG Biomarkers</measure>
    <time_frame>12 and 24 months of age</time_frame>
    <description>EEG measures of neuronal connectivity, comparing sirolimus with placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Biomarkers</measure>
    <time_frame>12 and 24 months of age</time_frame>
    <description>MRI measures of neuronal connectivity, comparing sirolimus with placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sirolimus Precision Dosing</measure>
    <time_frame>12 months of age</time_frame>
    <description>Validate the feasibility and effectiveness of sirolimus precision dosing in infants with TSC</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Tuberous Sclerosis Complex</condition>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sirolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>The investigational drug product to be used in this study is sirolimus, provided in oral suspension.</description>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 0-6 months of age at the time of enrollment (subject must be &lt;7 months of&#xD;
             chronological age at time of randomization and treatment initiation). Corrected age&#xD;
             must be at least 39 weeks (calculated by subtracting the number of weeks born before&#xD;
             40 weeks gestation from the chronological age).&#xD;
&#xD;
          2. Has a confirmed diagnosis of TSC based on established clinical or genetic criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of seizures (clinical or electrographic) at the time of enrollment or&#xD;
             identified on baseline EEG.&#xD;
&#xD;
          2. Has been treated in the past or is currently being treated at the time of enrollment&#xD;
             with conventional anticonvulsant medications (AEDs), systemic (oral) mTOR inhibitors&#xD;
             (such as rapamycin, sirolimus, or everolimus), ketogenic-related special diet, or&#xD;
             another anti-seizure therapeutic agent, device, or procedure.&#xD;
&#xD;
          3. Has taken any other investigational drug as part of another research study, within 30&#xD;
             days prior to the baseline screening visit.&#xD;
&#xD;
          4. Has a significant illness or active infection at the time of the baseline screening&#xD;
             visit&#xD;
&#xD;
          5. Has a history of significant prematurity, defined as gestational age &lt;30 weeks at the&#xD;
             time of delivery, or other significant medical complications at birth or during the&#xD;
             neonatal period that other than TSC would convey additional risk of seizures or&#xD;
             neurodevelopmental delay (i.e. HIE, severe neonatal infection, major surgery,&#xD;
             prolonged ventilatory or other life-saving supportive care or procedures).&#xD;
&#xD;
          6. Abnormal laboratory values at baseline (i.e., renal function, liver function, or bone&#xD;
             marrow production) that are in the opinion of the investigator clinically significant&#xD;
             and may jeopardize the safety of the study subject.&#xD;
&#xD;
          7. Prior, planned or anticipated neurosurgery within 3 months of the baseline visit&#xD;
&#xD;
          8. Has a TSC-associated condition for which mTOR treatment is clinically indicated (i.e.&#xD;
             SEGA or AML).&#xD;
&#xD;
          9. Subjects who are, in the opinion of the investigator, unable to comply with the&#xD;
             requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darcy A Krueger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martina Bebin, MD, MPA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Molly S Griffith, BA</last_name>
    <phone>513-636-9669</phone>
    <email>info@tscsteps.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Krefting, RN</last_name>
      <phone>526-533-0833</phone>
      <email>jessicakrefting@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>E. Martina Bebin, MD, MPA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angela Martinez</last_name>
      <phone>310-206-4037</phone>
      <email>angelamartinez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Rajsekar Rajamaran, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Winterbottom</last_name>
      <phone>650-498-9732</phone>
      <email>jwinter2@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Brenda Porter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emine Arcasoy</last_name>
      <phone>617-919-7624</phone>
      <email>emine.arcasoy@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Mustafa Sahin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University -- St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Novak</last_name>
      <phone>314-454-4267</phone>
      <email>novako@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Wong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hannah Riehl</last_name>
      <phone>919-962-8462</phone>
      <email>hannah.riehl@cidd.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Jamie Capal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly S Griffith, BA</last_name>
      <phone>513-636-9669</phone>
      <email>molly.griffith@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Darcy A Krueger, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas HSC at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saba Usmani</last_name>
      <phone>713-500-5766</phone>
      <email>saba.usmani@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hope Northrup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Medical Center, Cincinnati</investigator_affiliation>
    <investigator_full_name>Darcy Krueger</investigator_full_name>
    <investigator_title>IND Sponsor/Lead Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Tuberous Sclerosis Complex</keyword>
  <keyword>TSC</keyword>
  <keyword>epilepsy</keyword>
  <keyword>prevention</keyword>
  <keyword>mTOR</keyword>
  <keyword>sirolimus</keyword>
  <keyword>infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

